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Abstract
PURPOSE: To explore the relationship between morphological characteristics and histologic localization of metastasis 
within sentinel lymph nodes (SLN) and axillary spread in women with breast cancer.  METHODS: We selected 119 
patients with positive SLN submitted to complete axillary lymph node dissection from July 2002 to March 2007. We 
retrieved the age of patients and the primary tumor size. In the primary tumor, we evaluated histologic and nuclear grade, 
and peritumoral vascular invasion (PVI). In SLNs we evaluated the size of metastasis, their localization in the lymph node, 
number of foci, number of involved lymph nodes, and extranodal extension.  RESULTS: Fifty-one (42.8%) patients had 
confirmed additional metastasis in non-sentinel lymph nodes (NLSN). High histologic grade, PVI, intraparenchymatous 
metastasis, extranodal neoplastic extension and size of metastasis were associated with positive NLSN. SLN metastasis 
affecting the capsule were associated to low risk incidence of additional metastasis. After multivariate analysis, PVI 
and metastasis size in the SLN remained as the most important risk factors for additional metastasis.  CONCLUSIONS: 
The risk of additional involvement of NSLN is higher in patients with PVI and it increases progressively according the 
histologic localization in the lymph node, from capsule, where the afferent lymphatic channel arrives, to the opposite 
side of capsule promoting the extranodal extension.  Size of metastasis greater than 6.0 mm presents higher risk of 
additional lymph node metastasis.
Resumo
OBJETIVO: Explorar a relação entre características morfológicas e localização histológica da metástase dentro dos 
linfonodos sentinelas (LS) e disseminação axilar em mulheres com câncer de mama.  MÉTODOS: Foram selecionados 
119 pacientes com LS positivo, submetidas à dissecação completa dos linfonodos axilares entre Julho de 2002 a 
Março de 2007. Foram recuperados a idade das pacientes e o tamanho do tumor primário. No tumor primário, 
avaliamos os graus histológico e nuclear e a invasão vascular peritumoral (IVP). Nos LS, avaliamos o tamanho da 
metástase, sua localização no linfonodo, o número de focos metastáticos, número de linfonodos envolvidos e a extensão 
extranodal.  RESULTADOS: Cinquenta e um (42,8%) pacientes tiveram metástases adicionais confirmadas nos linfonodos 
não sentinelas (LNS). Alto grau histológico, IVP, metástase intraparenquimatosa, extensão extranodal e tamanho da 
metástase foram associados com LNS positivos. Metástase afetando a cápsula do LS foi associada com baixo risco 
de incidência de metástase adicional. Após análise multivariada, IVP e tamanho da metástase no LS foram os fatores de 
risco mais importantes para metástases adicionais nos LNS.  CONCLUSÕES: O risco de envolvimento adicional dos 
LNS é maior em pacientes com IVP e tal risco aumenta progressivamente de acordo com a localização histológica 
da metástase no LS, que inicia na cápsula, onde aporta o linfático aferente, e termina no lado oposto, promovendo 
a extensão extranodal. Tamanho de metástase maior ou igual a 6,0 mm revela maior risco de metástase nos LNS.      
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Introduction
Currently, one of the most important prognostic fac-
tors in breast cancer is the regional lymph node status. 
Lymph node metastasis determines the need for adjuvant 
therapy and the number of metastases may influence the 
type of therapy1. For decades, the complete axillary lymph 
node dissection (CALD) has been the standard of care in 
patients with invasive breast cancer in order to decide 
the quality of adjuvant therapy. A significant number of 
complications was the price to pay to have the knowledge 
of adequate axillary status2.
The sentinel lymph node (SLN) biopsy proved to be an 
excellent prognosticator for the outcome of breast cancer 
patients, without the need for a more morbid procedure 
as the formal CALD1,3. Therefore, the selective sentinel 
lymphadenectomy has become the standard approach 
for assessing axillary status in clinically node-negative 
breast cancer patients, with less morbidity4-6. On the 
other hand, CALD is the ideal recommended procedure 
for patients with SLN metastasis5. Different studies over 
the last few years have suggested that some patients with 
positive SLN can be treated without CALD7. The SLN is 
the only involved axillary node in 38 to 67% patients5,8-13. 
Some investigators have developed a nomogram to help 
the identification of subsets of patients who do not need 
CALD, however, results remain conflicting14. 
The presence or absence of metastases in the non-
sentinel lymph node (NSLN) seems to be dependent on 
some morphologic characteristics of the primary breast 
tumor and characteristics of the SLN metastases15. The 
purpose of this study was to explore the morphologic 
characteristics and the histologic localization of metas-
tases in the SLN, together with primary breast cancer 
features, in order to define subsets of patients that can 
achieve benefit from CALD.
 Methods
The study was retrospective and evaluated 546 
consecutive patients with invasive breast carcinomas 
and clinically negative axillary nodes, from July 2002 
to March 2007. All the patients were submitted to SLN 
biopsy and those with positive SLN underwent CALD. 
All the patients came from different private clinics 
from Campinas, the third city of the state of Sao Paulo, 
Brazil, with a 2010 population of more than one million. 
All the surgical specimens were processed and analyzed 
in the Instituto de Patologia de Campinas, a private 
laboratory in Campinas.
The subjects were selected from the list of women 
with positive SLN who underwent CALD. We excluded 
the women with negative SLN and those who refused to 
be submitted to CALD. SLN were negative in 405 pa-
tients (74.2%). One hundred-forty-one (25.8%) patients 
presented metastases in SLN. Of these cases, 14 patients 
had isolated tumor cells (2.5%), 24 had micrometastases 
(4.4%) and 103 had macrometastases (18.9%), defined 
according the American Joint Committee on Cancer 
(AJCC) criteria16.
Twenty-two of these patients were not submitted 
to CALD and were excluded from this study, 13 women 
with isolated tumor cells, 5 with micrometastases and 4 with 
small macrometastases in the SLN. One hundred-nineteen 
invasive breast carcinomas met the inclusion criteria for 
this study. The SLNs were identified by the blue dye 
and/or radiolabeled colloid and intraoperative gamma 
probe techniques. The SLNs were submitted to frozen 
section and paraffin examination. 
All SLN were entirely paraffin embedded after lon-
gitudinal or transverse sections at 2 to 3 mm intervals 
and fixation in 10% buffered formalin. Four-micrometer 
histological sections were stained by hematoxylin-eosin 
(H&E). The H&E slides were examined and, if the SLN 
was negative, six serial sections were taken from the par-
affin block at intervals of 50 μm. Immunohistochemical 
examination was performed in the first histologic section 
using AE1/AE3 antibody (Dako, Carpinteria, CA, 1:50 
dilution), employing the envision-peroxidase technique 
with antibody retrieval by humid heat. The remaining five 
sections were stained by H&E and examined microscopically.
We reviewed the hematoxylin-eosin (H&E) slides 
from the primary tumor, the SLN, and the complementary 
axillary lymph nodes (NSLN). The breast carcinoma was 
evaluated for tumor size (recorded by macroscopic descrip-
tion or measured from microscopic sections), histologic 
type, histological grade according Nottingham criteria17, 
nuclear grade and peritumoral vascular invasion. 
The positive SLNs were evaluated for size of meta-
static deposits, localization of the metastasis in the 
lymph node, number of foci, number of involved lymph 
nodes, and extranodal extension.  The size of metastases 
was measured by a glass millimeter ruler and classified 
according to AJCC as isolated tumor cells (measuring 
less than 0.2 mm at greatest diameter), micrometastases 
(measuring 0.2 to 2.0 mm) or macrometastases (measuring 
more than 2.0 mm and subdivided in 2.1 to 4.0 mm, 4.1 
to 6.0 mm, 6.1 to 8.0 mm, 8.1 to 10.0 mm and greater 
than 10.0 mm)16. The localization of metastases was 
defined as the main component of the neoplasia into the 
lymph node in the following categories: capsule, with 
or without subcapsular sinus (without extracapsular or 
parenchymatous extension); medullary sinus or sinusoids; 
parenchyma and extranodal extension (Figures 1 to 3). 
In addition to, the presence/absence of each localizations 
stated above, parenchymatous and extranodal involvement 
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were analyzed as categorical variables. The number of 
metastatic foci was counted and the largest focus was 
considered as the size of the metastasis. 
Careful examination of the CALD was carried out 
and the isolated axillary lymph nodes were dissected, 
fixed in 10% buffered formalin and entirely embedded 
in paraffin. After being sliced at 3 to 4 mm intervals in 
the longitudinal or transverse plane, lymph nodes mea-
suring less than 5 mm were submitted as one piece in 
toto. A single level of each block was stained with H&E.
All histological analysis were performed by two pa-
thologists (CAA and MA) and presented as a consensus.
Univariate analyses were performed using the χ2 
test or Fisher exact test for categorical variables to de-
termine the association between the morphology of the 
breast tumor and the SLN metastasis with the status of 
the NSLN. The respective values of crude odds ratios 
(and confidence intervals) were calculated. Association 
between histologic localization of metastasis in the SLN 
and the size of metastasis was analyzed by the Kruskal-
Wallis test. A multivariable logistic regression model 
was constructed to evaluate the association between the 
statistically significant variables in univariate analyses 
with the axillary status. Statistical analyses were performed 
using SAS Institute Incorporation SAS/STAT Software, 
and a p-value of less than 0.05 was considered significant.
The study was approved by the ethical committee 
for research of the School of Medical Sciences, from the 
State University of Campinas (Unicamp), protocol num-
ber 0262/2005.
Results
Patients’ ages ranged from 29 to 83 years with a mean 
age of 51 years. A total of 5 to 38 axillary lymph nodes 
were removed in CALD (mean: 15).  Fifty-one out of 119 
patients had additional metastases in CALD (42.8%). 
The size of breast tumors was evaluated according to 
AJCC16. For purpose of statistical analysis, pT1a cases 
(4 cases) were grouped with pT1b (30 cases) to form a 
homogeneous group (total of 33 cases or 27.7%). Sixty-
four tumors were pT1c (53.8%), and the pT2, pT3 and 
pT4 were grouped in 22 cases (18.4%). The histologic 
grade ranged as follows: grade I (6 cases; 5.0%) that were 
grouped with grade II (29 cases, 24.2%) for comparison 
with grade III (85 cases; 70.8%).  
The clinico-pathological features of the 119 patients 
included in the study according to the CALD involve-
ment are summarized in Table 1. High histologic grade 
and presence of peritumoral vascular invasion (PVI) were 
associated with neoplastic involvement of CALD. The 
classification of the metastasis according to their localiza-
tion within SLN is presented in Table 2. 
Figure 1. Metastatic neoplasia in the lymph node capsule, without exten-
sion to subjacent lymphoid tissue. Hematoxilin-eosin – original magni-
fication 100X.
Figure 2. Neoplasic involvement of subcapsular sinus and sinusoids of 
the lymph node. (A) Small neoplastic focus in subcapsular sinus. Hema-
toxilin-eosin – original magnification 400X; (B) Neoplasic involvement 
of subcapsular sinus and sinusoids highlighted by immunoexpression of 
cytokeratins AE1/AE3. Original magnification 100X.
A B
Figure 3. Intraparenchymatous involvement of sentinel lymph node. (A) 
Hematoxilin-eosin – original magnification 100X; (B) Same area high-
lighted by immunodetection of cytokeratins AE1/AE3.
A B
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Table 1. Association between breast tumor variables and patients’ age with non-sentinel axillary lymph node positivity
Total Positive axilla Negative axilla
p-value Crude OR (95%CI)
n n % n %
Age 0.6
Equal or less than 50 years 56 23 41.1 33 58.9 1.0
More than 50 years 62 28 45.2 34 54.8 1.2 (0.6–2.5)
Histologic type 0.6
Tubular 2 0 0.0 2 100.0
Lobular 8 4 50.0 4 50.0
Ductal 107 46 42.9 61 57.1
Mixed 2 1 50.0 1 50.0
Histologic grade 0.02
I/II 34 9 26.4 25 73.5 1.0
III 85 42 49.4 43 50.6 2.8 (1.8–6.7)
Nuclear grade 0.1
½ 56 20 35.7 36 64.3 1.0
3 63 31 49.2 32 50.8 1.7 (0.8–3.7)
Tumor size 0.1
pT1a/pT1b 33 10 30.3 23 69.7 1.0
pT1c 64 30 46.9 34 53.1 2.1 (0.9–5.1)
pT2/pT3/pT4 22 11 50.0 11 50.0 2.4 (0.8–7.3)
Peritumoral vascular invasion 0.0004
Absent 84 27 32.1 57 67.9 1.0
Present 35 24 68.6 11 31.4 4.6 (1.9–10.7)
Table 2. Classification of the metastasis according to their localization within sentinel 
lymph nodes
Localization of the metastasis n        % 
Group 1:  
Capsular and/or 
subcapsular
Capsule 2        1.7
Capsule and subcapsular sinus 5         4.2
Subcapsular sinus 8         6.7
Group 2:  
Sinusal
Capsule, subcapsular sinus and medullary sinusoids 1         0.8
Medullary sinus 4         3.4





Capsule, subcapsular sinus and parenchyma 1         0.8
Capsule and parenchyma 4         3.4
Subscapular and parenchyma 10       8.4
Medullary sinus and parenchyma 1         0.8




Parenchyma with extranodal extension 30     25.2
Total 119
Pathological characteristics of SLN like parenchy-
matous metastasis without or with extranodal extension 
(p=0.004 and respectively OR 4.3; 95%CI 0.91–21.02 
and OR 13.0; 95%CI 2.44–69.13) and size of metastasis 
equal or greater than 4 mm (p=0.01 and OR 2.9; 95%CI 
0.69–12.76) and 6 mm also (p=0.01 and OR 7.0; 95%CI 
1.60–31.33) were extremely associated with metastases in 
NSLN by univariate analyses. When the metastasis was 
associated with capsule involvement in SLN, the risk of 
additional metastases in NSLN were minimum (p=0.001 
and OR 0.05; 95%CI 0.003–0.8).
After multivariable analyses, when histologic grade, 
PVI, capsular involvement and localization of metastasis 
were included in the model, only PVI (OR 5.7; 95%CI 
2.3–14.0; p=0.0002) and parenchymal involvement with 
extranodal extension (OR 4.8; 95%CI 1.9–12.4; p=0.001) 
remained statistically significant. However, when the 
size of metastasis was included, only metastasis above 
6.0 mm (OR 5.8; 95%CI 2.5–13.6; p<0.0001) and PVI 
(OR 4.7; 95%CI 1.8–11.9; p=0.001) were predictors of 
additional metastasis.
Discussion
CALD remains the standard of care for SLN positive 
patients, even in most cases of axillary metastases are lim-
ited to the sentinel node9,13,18-21. Moreover, the omission 
of CALD in patients with limited metastatic disease did 
not affect overall or disease-free survival of patients with 
clinical T1-T2 breast cancer as showed in the American 
College of Surgeons Oncology Group Z0011 random-
ized trial7. The patients were treated with lumpectomy, 
adjuvant systemic therapy, and tangential-field whole-
breast radiation therapy. Patients were randomly assigned 
to the CALD group and to the SLN-alone group. In the 
CALD group, 97 of 355 patients (27.3%) had additional 
metastasis in lymph nodes removed by CALD7.
The high prevalence of NSLN metastases in our study 
(42.5%) can be explained because most of our SLN had 
macrometastases, considered an important risk factor of 
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metastasis in NSLN, as also suggested by Viale et al.22, 
who reported one of the highest prevalence of NSLN 
involvement of the literature (50.3%). 
The need for CALD is generally highly considered 
for young patients, but in our study, as well as in previous 
reports this does not seem to be a risk factor for additional 
metastasis14,22,23. However, young age is associated with 
a higher proportion of positive SLN24.
Other factors generally considered in the decision of 
a completion of axillary dissection are: size of primary 
tumor, PVI, size of metastasis and number of involved 
lymph nodes18-23,25-29. In our study, the mean size of breast 
tumor was 1.6 cm for cases with negative axillary NSLN 
and 1.8 cm for cases with positive NSLN axillary (varia-
tion between 0.1 and 6.0 cm). Two of the four patients 
with breast tumors less than or equal to 0.5 cm had ad-
ditional metastases in axillary lymph nodes, a possible 
reason why the association of primary tumor size with 
positive NSLN was not significant. One hundred patients 
with breast carcinomas of this study25 had metastases in 
22.6% of SLN, almost the same prevalence of our study. 
In that study25, as in ours, the size of breast cancer was 
not associated with positive NSLN. One hundred and 
eighty patients with SLN metastases of Fleming et al.27 
study found a significant association between the size 
of breast tumor and metastases in SLN, although breast 
tumor size was not relevant in predicting additional 
metastases in NSLN27.
However, primary tumor size was significantly as-
sociated with risk of NLSN metastasis in various stud-
ies19,20,23,26,29,30. All the studies found other characteristics 
equal or more important than the tumor size. Even in 
our study, we observed that biggest tumors were as-
sociated with additional metastasis. A statistical level 
of significance was not reached, probably due to the 
influence of other biological features. For example, in 
our cases, the high histologic grade of primary breast 
carcinomas was associated with higher fraction of ad-
ditional metastases. 
The size of metastatic deposits in SLN seems more 
important than the primary tumor size in predicting 
NLSN metastasis26. Our results confirm the impact of the 
size of metastasis as a risk factor to higher lymph node 
metastatic involvement. Only macrometastases equal 
or greater than 4 mm had important risk of additional 
metastases in NSLN, supporting the need of CALD in 
SLN macrometastases cases9,26. Despite the small number 
of cases with isolated tumor cells and micrometastases in 
the SLN (21 cases or 17.5%), we did not find a significant 
association with positive axilla, as in other studies22,31,32. 
PVI was observed in 34 (28.3%) patients of our 
study and it was significantly associated with additional 
metastases in the NSLN (p=0.0005). As discussed above 
regarding primary tumor size, the same controversies exist 
about the significance of PVI as a risk factor to additional 
lymph node metastasis. Several studies presented results 
similar to ours19,22,23,25,33,34, while others did not28,30,35.
The neoplastic emboli reach the SLN throughout the 
different lymphatic channels, migrate to the capsule of SLN 
first, then to the subcapsular sinus, after that, infiltrating 
the sinusoids and then, the lymph node parenchyma, dif-
fusely. Finally the tumor cells migrate beyond the opposite 
side of capsule promoting the extranodal extension. Our 
results, in a certain way, reflect this pathway as they show 
higher aggressiveness from capsule to extranodal exten-
sion. The histologic localization of metastases within the 
SLN was barely explored in literature. Diaz et al. observed 
that metastatic tumor had a higher probability of being 
present in the region of the inflow junction of the afferent 
lymphatic vessel and they suggested an optimization of 
the method for evaluating axillary sentinel lymph node 
specimens36. Although the data from this study do sug-
gest that tumor cells appear to localize preferentially to 
either the afferent lymphatic inflow junction or the area 
of the axillary SLN with the highest radioactive counts, a 
more practical method of processing the SLN would need 
to be developed to achieve a more focused evaluation of a 
single tissue block. Paish et al.37 developed an elegant and 
economic three-dimensional reconstruction (3DR) method 
to evaluate the spatial distribution of metastases in SLN. 
In this study, the afferent lymphatic pole was involved 
in 17/19 cases, but confined to the afferent pole only in 
7 cases. Metastases were present at the efferent pole in 
12/19 cases, and confined to the efferent pole only in two 
cases. Although the initial objectives of the study were 
to develop the method of 3DR and to understand of the 
early metastatic disease inside the lymph node, the authors 
incidentally found distinct metastatic growth patterns, 
classified as sinusoidal, nodular and diffuse. Although the 
number of cases was too small, their results suggested a 
poor prognosis associated to sinusoidal metastatic pattern 
and a good prognosis in the group of diffuse pattern37. 
Although a comparison does not seem appropriate, since 
the methods and objectives of our study were totally 
different, we found no significant risk of additional me-
tastasis in the cases with the sinusoidal localization of 
metastasis, a pattern similar to that described by Paish 
et al.37 as having a poor prognosis. 
We found fifteen cases of metastases located predomi-
nantly in the SLN capsule and/or subcapsular sinus, and 
13 (81%) of them did not have additional metastases in 
NSLN. For metastasis with a component in the capsule, 
even associated with more extensive involvement, the risk 
of disease in NSLN is lower. Therefore, we can conclude 
that SLN metastasis restricted to capsule is a good predic-
tor of no additional metastases in axillary lymph nodes. 
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On the other hand, metastasis in the SLN parenchyma 
(68%), was 5-times greater associated to the risk of additional 
NSLN involvement in univariate analyses and 1.5-times 
greater after multivariate analyses. Extranodal extension of 
the disease in the SLN was associated to a 4.2-time risk in 
univariate analysis. Consequently, it may be inferred that 
the metastasis situated in the capsule represent an initial 
stage of disease within the SLN, while the parenchymal 
and extranodal metastases represent an advanced stage of 
the disease, with bigger metastatic deposits and greater 
risk of additional involvement of NSLN. Metastasis above 
6.0 mm together with the presence of PVI were the most 
powerful predictors of additional metastasis. There are some 
doubts about histological localization of metastasis within 
the SLN, as a tentative of identification of more aggressive 
cases and as an explanation about neoplastic involvement 
of SLN restricted to the capsule could be considered a real 
metastasis or it could correspond to mechanical transport 
of cells from the primary tumor.
At this moment, we did not analyze the pathological 
features impact on patients survival or the risk of regional 
recurrence. Further studies could investigate a possible role 
of the histological localization of metastasis, particularly 
the extranodal involvement, on the recurrence.
Our results show that the localization of metastatic 
cells within SLN is an important predictor of risk of ad-
ditional metastasis and the findings are consistent with 
the pattern of metastatic dissemination through afferent 
vessels to extranodal spread.
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